ArticleEClinicalMedicine2021
Global burden of upper respiratory infections in 204 countries and territories, from 1990 to 2019.
Article in EClinicalMedicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 193 papers, 7 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
193 citing papers in PubMed, 7 syntheses or guidelines pooled it, 310 citations in OpenAlex.
- Diagnostic accuracy of point-of-care tests for acute respiratory infection: a systematic review of reviews.Health technology assessment (Winchester, England) · 2026Pooled it
- Global meta-analysis of short-term associations between ambient temperature and pathogen-specific respiratory infections, 2004 to 2023.Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin · 2025Pooled it
- Optimal methods of vitamin D supplementation to prevent acute respiratory infections: a systematic review, dose-response and pairwise meta-analysis of randomized controlled trials.Nutrition journal · 2024Pooled it
- Chinese medicineFrontiers in pharmacology · 2024Pooled it
- Travel-related respiratory symptoms and infections in travellers (2000-22): a systematic review and meta-analysis.Journal of travel medicine · 2023Pooled it
- Orally Ingested Probiotics, Prebiotics, and Synbiotics as Countermeasures for Respiratory Tract Infections in Nonelderly Adults: A Systematic Review and Meta-Analysis.Advances in nutrition (Bethesda, Md.) · 2022Pooled it
- Predisposing factors to acquisition of acute respiratory tract infections in the community: a systematic review and meta-analysis.BMC infectious diseases · 2021Pooled it
- Sarilumab in Polyarticular-Course Juvenile Idiopathic Arthritis: Dose-Finding and 1-Year Analysis of a Phase 2b, Open-Label, Multicenter Study.Arthritis care & research · 2026Trial
- Trial
- A probiotic containing L. plantarum and P. acidilactici strains for treating upper respiratory infection in children aged 6 months to 5 years: a randomized, double-blind trial.European journal of pediatrics · 2025Trial
- Efficacy and Safety Maintained up to 3 Years in Adults with Paroxysmal Nocturnal Hemoglobinuria Receiving Pegcetacoplan.Advances in therapy · 2025Trial
- Trial
- Efficacy of regular gargling with a cetylpyridinium chloride plus zinc containing mouthwash can reduce upper respiratory symptoms.PloS one · 2025Trial
- Xylitol for the prevention of acute otitis media episodes in children aged 1-5 years: a randomised controlled trial.Archives of disease in childhood · 2024Trial
- An open-label, Phase 3 trial of TAK-003, a live attenuated dengue tetravalent vaccine, in healthy US adults: immunogenicity and safety when administered during the second half of a 24-month shelf-life.Human vaccines & immunotherapeutics · 2023Trial
- Trial
- Variations in the association between standalone and coexisting forms of undernutrition and common infectious morbidities among children in sub-Saharan Africa.Global health research and policy · 2026Article
- Associations between environmental exposure, lifestyle, and the risk of respiratory infections among 67890 adults: A population-based cohort analysis using UK Biobank data.Global health research and policy · 2026Article
- Optimization of Xiaoer Lingyin granule formulation using single-factor and response surface methodology.RSC advances · 2026Article
- Optimization of the antiviral spectrum of cyclophilin inhibitors targeting respiratory viruses.Antimicrobial agents and chemotherapy · 2026Article
133 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundUpper respiratory infections (URIs) are among the most common diseases. However, the related burden has not been comprehensively evaluated. Thus, we designed the present study to describe the global and regional burden of URIs from 1990 to 2019.
methodsA secondary analysis was performed on the incidence, mortality, and disability-adjusted life years (DALYs) of URIs in different sex and age groups, from 21 geographic regions, 204 countries and territories, between 1990 and 2019, using the Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) 2019. Countries and territories were categorized according to Socio-demographic Index (SDI) quintiles.
findingsGlobally, the incident cases of URIs reached 17·2 (95% uncertainty interval: 15·4 to 19·3) billion in 2019, which accounted for 42·83% (40·01% to 45·77%) cases from all causes in the GBD 2019 study. The age-standardized incidence rate remained stable from 1990 to 2019, while significant decreases were found in the mortality and DALY rate. The highest age-standardized incidence rates from 1990 to 2019 and the highest age-standardized DALY rates after 2011 were observed in high SDI regions. Among all the age groups, children under five years old suffered from the highest incidence and DALY rates, both of which were decreased with increasing age. Fatal consequences of URIs occurred mostly in the elderly and children under five years old.
interpretationThe present study provided comprehensive estimates of URIs burden for the first time. Our findings, highlighting the substantial incidence and considerable DALYs due to URIs, are expected to attract more attention to URIs and provide future explorations in the prevention and treatment with epidemiological evidence.
fundingThe study was funded by the National Natural Science Foundation of China (81770057).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.